Stivarga and Hydramine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Stivarga (regorafenib) and Hydramine (diphenhydramine hydrochloride). Common drug interactions include dyspepsia among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Stivarga and Hydramine. It is created by eHealthMe based on reports of 36 people who take the same drugs from the FDA, and is updated regularly.

What is Stivarga?

Stivarga has active ingredients of regorafenib. eHealthMe is studying from 9,539 Stivarga users. Check the latest studies of Stivarga.

What is Hydramine?

Hydramine has active ingredients of diphenhydramine hydrochloride. It is often used in insomnia. eHealthMe is studying from 114,900 Hydramine users. Check the latest studies of Hydramine.



On Jul, 13, 2026

36 people who take Stivarga and Hydramine together, and have interactions are studied.

Stivarga and Hydramine drug interactions.

What are the common drug interactions of Stivarga and Hydramine, by gender? *:

female:

  1. Dyspepsia (indigestion)
  2. Faeces hard
  3. Gastritis (inflammation of stomach)
  4. Hot flush (sudden feelings of heat)
  5. Hyperhidrosis (abnormally increased sweating)
  6. Hypertension (high blood pressure)
  7. Incision site pain
  8. Incision site pruritus (itching around the incision site)
  9. Lower gastrointestinal haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding)
  10. Memory impairment

male:

  1. Fatigue (feeling of tiredness)
  2. Pain in extremity
  3. Weight decreased
  4. Arrhythmia (irregular heartbeat)
  5. Chest discomfort
  6. Surgery
  7. Urinary incontinence (inability to control the flow of urine and involuntary urination)
  8. Dry skin
  9. Musculoskeletal disorder (disease of the body's muscles, joints, tendons, ligaments and nerves)
  10. Skin exfoliation (removal of the oldest dead skin cells)

What are the common drug interactions of Stivarga and Hydramine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Abdominal pain upper
  2. Fatigue (feeling of tiredness)
  3. Pain in extremity
  4. Rash
  5. Skin exfoliation (removal of the oldest dead skin cells)
  6. Dry skin
  7. Musculoskeletal disorder (disease of the body's muscles, joints, tendons, ligaments and nerves)
  8. Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
  9. Decreased appetite
  10. Eating disorder

50-59:

  1. Colorectal cancer metastatic (cancer of colon and rectal spreads to other parts)
  2. Neuropathy peripheral (surface nerve damage)
  3. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  4. Ammonia increased
  5. Blood bilirubin increased
  6. Colon cancer metastatic (cancer of colon spreads to other part of body)
  7. Asthenia (weakness)
  8. Decreased appetite
  9. Rash erythematous (redness of the skin)
  10. Sluggishness (lacking alertness)

60+:

  1. Blood pressure increased
  2. Fatigue (feeling of tiredness)
  3. Surgery
  4. Disorientation (disability in which the senses of time, direction, and recognition of people and places)
  5. Erythema (redness of the skin)
  6. Faeces hard
  7. Haemorrhoids (a swollen vein or group of veins in the region of the anus)
  8. Headache (pain in head)
  9. Dysphonia (speech disorder attributable to a disorder of phonation)
  10. Pulmonary mass

What are the existing conditions these people have? *

  1. Colon Cancer: 11 people, 30.56%
  2. Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 10 people, 27.78%
  3. Rectal Cancer (cancer of rectum): 8 people, 22.22%
  4. Inflammation: 3 people, 8.33%
  5. Hypersensitivity: 3 people, 8.33%
  6. Gastrointestinal Stromal Tumor: 3 people, 8.33%
  7. Stress And Anxiety: 2 people, 5.56%
  8. Pain: 2 people, 5.56%
  9. Nausea (feeling of having an urge to vomit): 2 people, 5.56%
  10. Metastases To Retroperitoneum (cancer spreads to retroperitonium): 2 people, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Stivarga and Hydramine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Stivarga and Hydramine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Stivarga:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Hydramine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Stivarga and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Hydramine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on regorafenib and diphenhydramine hydrochloride (the active ingredients of Stivarga and Hydramine, respectively), and Stivarga and Hydramine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: